Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 11.5% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 121,293 shares of the company’s stock after acquiring an additional 12,503 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.26% of Cardiff Oncology worth $324,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Blair William & Co. IL raised its holdings in Cardiff Oncology by 32.2% during the second quarter. Blair William & Co. IL now owns 227,630 shares of the company’s stock worth $505,000 after purchasing an additional 55,450 shares in the last quarter. Point72 DIFC Ltd purchased a new position in shares of Cardiff Oncology during the 2nd quarter worth approximately $27,000. GSA Capital Partners LLP lifted its holdings in shares of Cardiff Oncology by 432.7% in the 3rd quarter. GSA Capital Partners LLP now owns 186,650 shares of the company’s stock valued at $498,000 after buying an additional 151,613 shares during the period. Rhumbline Advisers purchased a new stake in shares of Cardiff Oncology in the second quarter valued at approximately $102,000. Finally, Cubist Systematic Strategies LLC grew its holdings in Cardiff Oncology by 112.9% during the second quarter. Cubist Systematic Strategies LLC now owns 68,730 shares of the company’s stock worth $153,000 after acquiring an additional 36,441 shares during the period. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Cardiff Oncology Stock Performance

Cardiff Oncology stock opened at $4.49 on Friday. The firm has a market capitalization of $229.59 million, a price-to-earnings ratio of -4.78 and a beta of 1.89. Cardiff Oncology, Inc. has a fifty-two week low of $1.37 and a fifty-two week high of $6.42. The stock’s fifty day moving average is $3.05 and its two-hundred day moving average is $2.66.

Insider Activity at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace bought 350,115 shares of the business’s stock in a transaction on Wednesday, December 11th. The stock was bought at an average price of $2.60 per share, for a total transaction of $910,299.00. Following the completion of the transaction, the director now owns 1,047,876 shares in the company, valued at approximately $2,724,477.60. The trade was a 50.18 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

CRDF has been the topic of several research analyst reports. Craig Hallum began coverage on shares of Cardiff Oncology in a research report on Friday, September 6th. They set a “buy” rating and a $8.00 target price on the stock. HC Wainwright lowered their target price on shares of Cardiff Oncology from $14.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Finally, Piper Sandler increased their target price on shares of Cardiff Oncology from $7.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, December 13th.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.